15:47 , Aug 23, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Inflammation Patient sample and cell culture studies suggest nitro-fatty acids could help treat STING-associated vasculopathy with onset in infancy (SAVI), an inflammatory disease caused by gain-of-function STING mutations. In fibroblasts from SAVI patients, nitro-fatty...
19:11 , Mar 9, 2018 |  BC Week In Review  |  Clinical News

Gilead's TLR7 agonist shows promise against HIV in shock and kill combo in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
22:57 , Mar 5, 2018 |  BC Extra  |  Preclinical News

HIV shock and kill combo shows promise in monkeys

Researchers showed that a broadly neutralizing antibody (bNAb) delayed HIV rebound in a "shock and kill" combination with toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) from Gilead Sciences Inc. (NASDAQ:GILD) after discontinuation of antiretroviral therapy...
19:21 , Jan 17, 2018 |  BC Innovations  |  Distillery Therapeutics

Inflammation

INDICATION: Allergy Cell culture studies suggest a CD23-mimicking single-domain antibody against IgE could help treat allergy. The single-domain neutralizing antibody mimics CD23, the low-affinity Fc receptor for IgE, to bind IgE with a K d...
15:44 , Aug 11, 2017 |  BC Week In Review  |  Clinical News

Mologen's lefitolimod misses in extension for HIV infection

Mologen AG (Xetra:MGN) reported data from 12 patients with chronic HIV-1 infection on antiretroviral therapy (ART) in a 24-week extension of the open-label, Danish Phase Ib/IIa TEACH trial showing that twice-weekly 60 mg subcutaneous lefitolimod...
23:03 , Aug 9, 2017 |  BC Extra  |  Clinical News

Mologen sinks on lefitolimod HIV miss

Mologen AG (Xetra:MGN) dropped €0.81 (21%) to €3.06 on Wednesday after its lefitolimod (MGN1703) missed the primary endpoint in an extension of the Phase Ib/IIa TEACH trial to treat HIV infection in patients on antiretroviral...
23:05 , Feb 2, 2017 |  BC Innovations  |  Strategy

Cure cash

With the goal now to clear rather than just suppress HIV, Gilead Sciences Inc. is using a $22 million grant program to back the scientific strategies it thinks are most likely to empty the HIV...
08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Nuclear factor of κ light polypeptide gene enhancer in B cells inhibitor ζ (NFKBIZ; IKBζ)

Autoimmune disease Patient sample and mouse studies suggest inhibiting NFKBIZ could help treat psoriasis. NFKBIZ levels were higher in skin samples from 17 psoriasis patients than in samples from healthy controls. In two mouse models...
07:00 , Oct 12, 2015 |  BC Week In Review  |  Company News

Aarhus University Hospital, Exiqon deal

Aarhus granted Exiqon exclusive rights to develop and commercialize two sets of biomarkers related to the diagnosis of prostate cancer via urine and tissue samples. Exiqon said the next step will be to validate the...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Company News

Aarhus University Hospital, Exiqon deal

Exiqon received exclusive, worldwide rights to prostate cancer biomarkers comprising gene-specific methylation patterns for life science and diagnostic applications from the hospital. Exiqon plans to use its LNA enhanced qPCR platform to complete analytical validation...